Research programme: Parkinson's disease therapeutics - Servier/University of Barcelona
Latest Information Update: 28 Jul 2024
At a glance
- Originator Servier; University of Barcelona
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Parkinson's-disease in France
- 28 Jul 2024 No recent reports of development identified for research development in Parkinson's-disease in Spain
- 30 Jun 2020 Servier and University of Barcelona collaborate for the development of Parkinson's disease therapeutics